A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs

European Journal of Cancer Prevention

Volumn 11, Issue 2, 2002, Pages 117-123

  La Vecchia, C L ^a,b   Tavani, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Gastric cancer; H2 receptor antagonists; Omeprazole; Risk

Indexed keywords

ANTIULCER AGENT; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

CANCER RISK; DATA ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

CASE-CONTROL STUDIES; CIMETIDINE; CLINICAL TRIALS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; MALE; PEPTIC ULCER; STOMACH NEOPLASMS;

EID: 0036246407     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200204000-00002     Document Type: Review

References (59)

1. Short-course cimetidine and survival with colorectal cancer
2. Pilot study - Cimetidine enhances lymphocyte infiltration of human colorectal carcinoma. Results of a small randomized control trial
3. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls
4. Mortality from gastric cancer following gastric surgery for peptic ulcer
5. Proton-pump inhibitor-associated gastric polyps: A retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics
6. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
7. Cimetidine and gastric cancer: Preliminary report from postmarketing surveillance study
8. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report
9. Postmarketing surveillance of the safety of cimetidine: Mortality during second, third, and fourth years of follow up
10. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report
11. Modern anti-ulcer regimens and gastric carcinoma-is there a delay in definitive treatment
12. Cimetidine and gastric cancer
13. Fundic gland polyps developing during omeprazole therapy
14. 2receptor antagonists, and risk of esophageal and gastric cancer
15. Histamine-2-receptor antagonists. Standard therapy for acid-peptic diseases. (2)
16. Histamine-2-receptor antagonists and oesophageal cancer
17. Metastatic malignant melanoma: Regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine
18. Gastric cancer in patients who have taken cimetidine
19. Proton pump inhibitors may mask early gastric cancer
20. Comparison of antiproliferative effects of 1-histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells
21. Gastric cancer after cimetidine in patient with two negative pretreatment biopsies
22. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites
23. Histamine, cimetidine and colorectal cancer
24. Gastric cancer in patients who have taken cimetidine
25. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay area, California
26. Oesophageal mucosal pathology in a population at risk for gastric oesophageal carcinoma
27. Histamine-2 receptor antagonists and gastric cancer
28. Esophagitis and cancer of the esophagus
29. Antisecretory drugs and gastric cancer
30. Histamine-2-receptor antagonists and gastric cancer risk
31. Partial gastrectomy and subsequent gastric cancer risk
32. Histamine-2-receptor antagonists and gastric cancer: Update and note on latency and covariates
33. Gastrectomy and subsequent risk of oesophageal cancer in Milan
34. Stomach cancer after partial gastrectomy for benign ulcer disease
35. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: A pilot study
36. Delays in the diagnosis of oesophagogastric cancer: A consecutive case series
37. Omeprazole
38. Cancer occurrence in a cohort of patients surgically treated for peptic ulcer
39. Cancer occurrence in a cohort of patients treated with cimetidine
40. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users
41. Gastric cancer in patients who have taken cimetidine
42. Gastric cancer in patients who have taken cimetidine
43. Gastric juice N-nitrosamines in health and gastroduodenal disease
44. Effect of cimetidine on gastric juice N-nitrosamine concentration
45. Cimetidine and gastric cancer
46. In vivo experimental demonstration that hyperhistamism counteracts tumor growth
47. Gastric cancer in patients who have taken cimetidine
48. Cimetidine use and gastric cancer
49. Gastric cancer and cimetidine: Does delay in diagnosis matter?
50. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind randomized pilot study
51. Cimetidine and colorectal cancer
52. Gastric cancer in patients who have taken cimetidine
53. Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients
54. Effect of cimetidine on survival after gastric cancer
55. Confounding by indication
56. Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esopahgeal sphincter (United States)
57. The response of early gastric cancer to proton-pump inhibitor